Innovassynth Technologies (India) Ltd
Incorporated in 2008, Innovassynth Technologies Ltd is a Contract Research, Development and Manufacturing Organization (CRDMO) specializing in pharmaceutical intermediates, oligonucleotide building blocks and specialty chemicals.
- Market Cap ₹ 939 Cr.
- Current Price ₹ 101
- High / Low ₹ 126 / 45.0
- Stock P/E
- Book Value ₹ 10.2
- Dividend Yield 0.00 %
- ROCE -24.9 %
- ROE -40.6 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 1.34% over last quarter.
Cons
- Stock is trading at 9.94 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -20.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 127 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -24 |
| OPM % | 22% | -24% | ||||||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Profit before tax | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -40 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -28% |
| -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -29 | |
| EPS in Rs | -0.08 | -0.11 | -0.11 | -0.13 | -0.18 | -0.18 | -0.17 | -0.22 | -0.22 | -0.23 | -0.33 | -3.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -3311% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 68% |
| 3 Years: | 68% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -15% |
| 3 Years: | -21% |
| Last Year: | -41% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 28 | 75 |
| Reserves | -1 | -1 | -2 | -2 | -4 | -4 | -4 | 11 | 10 | 9 | 15 | 19 |
| 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 113 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 71 | |
| Total Liabilities | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 278 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Investments | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 143 | |
| Total Assets | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 278 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -39 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 29 | |
| Net Cash Flow | -0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | 0 | -19 |
| Free Cash Flow | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -45 |
| CFO/OP | 95% | 85% | 73% | 48% | 129% | 106% | 100% | 84% | 89% | 92% | 174% | 162% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 112 | |||||||||||
| Inventory Days | 530 | |||||||||||
| Days Payable | 376 | |||||||||||
| Cash Conversion Cycle | 266 | |||||||||||
| Working Capital Days | -52 | |||||||||||
| ROCE % | -1% | -1% | -1% | -1% | -2% | -2% | -1% | -1% | -1% | -1% | -1% | -25% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Turnover (Revenue) Rs. Crore |
|
||||||
| Capital Structure (Gearing Ratio) times |
|||||||
| Customer Concentration (Top Customer Revenue Share) % |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
31 May - Investor Presentation for the quarter and year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Newspaper publication of financial results for the quarter and year ended March 31, 2026.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - FY26 secretarial compliance report notes ₹10,000 BSE fine for delayed board meeting intimation.
-
Disclosure Regarding Notice Received From BSE Limited For Levy Of Fine Under SEBI (LODR) Regulations 2015 And Board Comments Thereon.
29 May - BSE levied Rs 11,800 fine for March 2026 SEBI LODR non-compliances; company paid it.
- Financial Result For The Quarter And Year Ending March 31, 2026. 29 May
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Innovassynth Technologies is a chemistry-focused CRDMO company engaged in research, development, and manufacturing across three key verticals — pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It provides end-to-end services including custom synthesis, process development, scale-up, and commercial manufacturing for global life sciences and advanced materials customers. The company's oligonucleotide vertical focuses on nucleosides and amidites used in DNA/RNA therapeutics, while the specialty chemicals vertical serves applications in polyolefins, organometallic catalysts, and semiconductor materials. ITL uses chemistry capabilities, process innovation, and manufacturing expertise, to position itself as a long-term partner for global pharmaceutical and specialty chemical companies.